Day: December 14, 2021

This Expansion of Field Trip Services Will Help The Company Become a Leading Center For Psychedelic Clinical Trials TORONTO, Dec. 14, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, today announced the launch of its Site Management Organization Services (“SMO Services”). The SMO Services will enable companies and researchers developing psychedelic therapies to use Field Trip’s world class facilities, and expertly trained medical and therapy teams, to conduct clinical trials. The SMO Services will be led by Stéphan Côté, who has joined Field Trip as Head of Quality. “There are presently over one hundred psychedelic clinical trials in planning or underway, and many more likely, as research into psychedelic...

Pharmaceutical industry leader brings more than 30 years of quality, regulatory and manufacturing experienceKimball Hall, Vera Therapeutics board memberKimball Hall, Vera Therapeutics board member, president and chief operating officer of AbzenaBRISBANE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Kimball Hall to its board of directors. Ms. Hall is a seasoned executive and a chemistry, manufacturing, and controls (CMC) expert. Formerly holding leadership positions at Genentech and Amgen, she is currently president and chief operating officer of Abzena, a biopharmaceutical focused contract...

Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022 NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis (RMS). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022. The FDA also notified the Company that it is not currently planning to hold an advisory committee meeting to discuss this application. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “We are excited to share that we have received formal communication from the FDA, and the...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dates May 11, 2021, to its short form base shelf prospectus dated May 7, 2021, and amended and restated on May 25, 2021. All amounts are expressed in Canadian dollars unless otherwise noted.HEXO reports $50.2 million in total net revenue for Q1’22, an increase of 29% compared to the fiscal quarter ended July 31, 2021 (Q4’21) Maintains #1 Market Share position in Canada1 Announces new strategic plan, “The Path Forward” to strengthen its balance sheet and accelerate its transformation to become a cash flow positive company within the next four quarters.____________1 Based on Headset data for the quarter of August to October 2021 GATINEAU, Quebec, Dec. 14, 2021 (GLOBE NEWSWIRE) — HEXO Corp (TSX: HEXO; NASDAQ: HEXO)...

SATO Corporation, press release 14 December 2021 at 2:15 pm SATO Corporation and OP Corporate Bank plc have agreed upon a bilateral loan of €75 million without asset-based securities and the margin is linked to achieving SATO’s main sustainability targets. The agreement of the seven-year loan was signed in Helsinki on 13 December 2021, and the cash proceeds will be used for the Group’s general financing purposes. For more information, please contact: SATO CorporationMarkku Honkasalo, CFO, tel. +358 201 34 4226Henry Lindqvist, Group Treasurer, tel. +358 50 317 2352 SATO is one of Finland’s leading rental housing providers. SATO aims to offer a comprehensive choice of rental housing and an excellent customer experience. At year-end 2020, SATO owned close to 26,800 apartments in Finland’s largest growth centres and in St. Petersburg. We...

Patent Readies Company for Next Generation of PoNS Therapy NEWTOWN, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,197,994, which is directed to systems for providing non-invasive neurorehabilitation of a patient. The patent is similar in scope to prior Helius patents for the Portable Neuromodulation Stimulator (PoNS) device but expressly recites that the communications between the mouthpiece and controller are done wirelessly. “We are pleased to announce our new patent, which will allow for a wireless connection between the mouthpiece and controller of our PoNS device,” said Dane Andreeff, President and Chief...

BETHLEHEM, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2022 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 17, 2022. The record date for the Meeting will be March 27, 2022. Only stockholders of record as of the close of business on the record date will be entitled to vote at the 2022 Annual Meeting, or any adjournment(s) or postponement(s) of the Meeting. This will be a completely virtual meeting, conducted as a live webcast. Further details regarding the Meeting will be provided at a later date. About OraSure Technologies OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly owned subsidiaries,...

Dlaboratory Sweden AB (publ) provides a solution that can significantly help distribution system operators in avoiding disconnection issues that originates from displacement voltages. In a power grid, protection relays are critical components which are supposed to detect and disconnect faulty feeders. Unfortunately, they do not detect all faults. For example, the relay protection systems can be incorrectly configured or not sensitive enough for certain intermittent earth faults, why a faulty feeder may not be disconnected in a proper way leading to a high displacement voltage tripping the whole substation. The problem of unselective tripping is a hot topic of discussion and, among others, Vattenfall has drawn attention to the problem in a thesis which can be read here: FULLTEXT01.pdf (diva-portal.org  (In Swedish) dLab solution to unselective...